Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL844829 | 0.98 | ALDH1A1 (0.50) | ALDH1A1TSHRTHRBSMN1; SMN2MAPT | |
| SCHEMBL10550382 | 0.95 | ALDH1A1 (0.51) | ALDH1A1TSHRTHRBSMN1; SMN2MAPT | |
| SCHEMBL482106 | 0.93 | ALDH1A1 (0.53) | ALDH1A1TSHRTHRBSMN1; SMN2MAPT | |
| SCHEMBL28810775 | 0.92 | ALDH1A1 (0.52) | ALDH1A1TSHRTHRBSMN1; SMN2MAPT | |
| SCHEMBL19474878 | 0.92 | ALDH1A1 (0.52) | ALDH1A1TSHRTHRBSMN1; SMN2MAPT | |
| SCHEMBL11848105 | 0.92 | ALDH1A1 (0.52) | ALDH1A1TSHRTHRBSMN1; SMN2MAPT | |
| SCHEMBL5656419 | 0.92 | ALDH1A1 (0.52) | ALDH1A1TSHRTHRBSMN1; SMN2MAPT | |
| SCHEMBL844467 | 0.90 | ALDH1A1 (0.54) | ALDH1A1TSHRTHRBSMN1; SMN2MAPT | |
| SCHEMBL879035 | 0.90 | SMN1; SMN2 (0.42) | ALDH1A1TSHRSMN1; SMN2MAPTKMT2A | |
| SCHEMBL844853 | 0.90 | SMN1; SMN2 (0.42) | ALDH1A1TSHRSMN1; SMN2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060205811-A1 | Compounds that stimulate glucose utilization and methods of use | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2006-09-14 | — | — | US | claimed |
| US-20060173208-A1 | Compounds that stimulate glucose utilization and methods of use | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2006-08-03 | — | — | US | claimed |
| US-7084173-B2 | Compounds that stimulate glucose utilization and methods of use | THE GOVERNORS OF THE UNIVERITY OF ALBERTA (CA) | 2006-08-01 | — | — | US | claimed |
| EP-1499580-A1 | COMPOUNDS THAT STIMULATE GLUCOSE UTILIZATION AND METHODS OF USE | UNIVERSITY OF ALBERTA (CA) | 2005-01-26 | — | — | EP | claimed |
| US-20040116517-A1 | Compounds that stimulate glucose utilization and methods of use | UNIVERSITY OF ALBERTA (CA) | 2004-06-17 | — | — | US | claimed |
| WO-2003082800-A1 | COMPOUNDS THAT STIMULATE GLUCOSE UTILIZATION AND METHODS OF USE | THE UNIVERSITY OF ALBERTA (CA) | 2003-10-09 | — | — | WO | claimed |
| US-20030191182-A1 | Compounds that stimulate glucose utilization and methods of use | GOVERNORS OF THE UNIVERSITY OF ALBERTA, THE (CA) | 2003-10-09 | — | — | US | claimed |
| US-8202901-B2 | Compounds that stimulate glucose utilization and methods of use | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2012-06-19 | — | — | US | disclosed |
| US-8202901-B2 | Compounds that stimulate glucose utilization and methods of use | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2012-06-19 | — | — | US | disclosed |
| US-20090258835-A1 | COMPOUNDS THAT STIMULATE GLUCOSE UTILIZATION AND METHODS OF USE | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA TEC EDMONTON (CA) | 2009-10-15 | — | — | US | disclosed |
| US-20090258835-A1 | COMPOUNDS THAT STIMULATE GLUCOSE UTILIZATION AND METHODS OF USE | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA TEC EDMONTON (CA) | 2009-10-15 | — | — | US | disclosed |
| US-7524885-B2 | Compounds that stimulate glucose utilization and methods of use | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2009-04-28 | — | — | US | disclosed |
| US-7524885-B2 | Compounds that stimulate glucose utilization and methods of use | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2009-04-28 | — | — | US | disclosed |
| US-7473706-B2 | Compounds that stimulate glucose utilization and methods of use | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2009-01-06 | — | — | US | disclosed |
| US-7473706-B2 | Compounds that stimulate glucose utilization and methods of use | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2009-01-06 | — | — | US | disclosed |
| US-7473706-B2 | Compounds that stimulate glucose utilization and methods of use | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2009-01-06 | — | — | US | disclosed |
| US-20030191182-A1 | Compounds that stimulate glucose utilization and methods of use | GOVERNORS OF THE UNIVERSITY OF ALBERTA, THE (CA) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258835-A1 | COMPOUNDS THAT STIMULATE GLUCOSE UTILIZATION AND METHODS OF USE | GPR119, SLC2A4, SLC2A1 | ALDH1A1 1918/4885TSHR 623/4885THRB 522/4885 |
| US-20060173208-A1 | Compounds that stimulate glucose utilization and methods of use | GPR119, SLC2A4, SLC2A1 | ALDH1A1 1990/4885TSHR 512/4885THRB 452/4885 |
| US-20060205811-A1 | Compounds that stimulate glucose utilization and methods of use | GPR119, SLC2A4, SLC2A1 | ALDH1A1 1990/4885TSHR 512/4885THRB 452/4885 |
| US-20030191182-A1 | Compounds that stimulate glucose utilization and methods of use | GPR119, SLC2A3, CYCS | ALDH1A1 2045/4885TSHR 732/4885THRB 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.